Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Total Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Total Liabilities for 2 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 32.04% to $19.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.4 million, a 32.04% decrease, with the full-year FY2025 number at $19.4 million, down 32.04% from a year prior.
  • Total Liabilities was $19.4 million for Q4 2025 at Evommune, up from $10.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $122.5 million in Q3 2024 to a low of $10.7 million in Q3 2025.